07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Retinoid X receptor-α (RXRA; RXRα); tumor necrosis factor (TNF) α

Cancer INDICATION: Cancer In vitro and mouse studies suggest a nitrostyrene-based RXRα inhibitor could help treat cancer. A chemical screen of a small molecule library identified a nitrostyrene analog that bound RXRα with a Kd...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Retinoid X receptor-a (RXRA; RXRa) In vitro and mouse studies identified derivatives of the generic NSAID sulindac that specifically inhibit RXRa and could help...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer Retinoid X receptor-g (RXRG; RXRg) In vitro and mouse studies suggest spironolactone or RXRg agonists could help treat colon cancer. In colon cancer...
08:00 , Dec 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Retinoid X receptor-a (RXRA; RXRa); tumor necrosis factor-a (TNF-a) Cell culture studies suggest a xanthone called CF31, isolated from the Cratoxylum formosum plant, could...
07:00 , Jun 24, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Retinoid X receptor-a (RXRA; RXRa) In vitro and mouse studies suggest that analogs of the NSAID sulindac could help treat cancer. In cultured...